
Dubai, Silicon Oasis Building A1 +9B2781979791

Jordon, Ammon,
Abdullah Ghosheh, 4ó. 101
+97145490330
Also Aviable in






82 Unit A, James Carter Road, Mildenhall Industrial Estate, Suffolk, United Kingdom, IP28 7DE www.DNADiet.uk
This is the latest DNA-related food intolerance test technology that will guarantee a weight loss of the kilograms you subscribed for. This test is made on 3 different categories 10 KGs, 20 KGs and an ideal body test that will guarantee you reach the weight you registered for in a fast and healthy way
First Head | Second Head |
---|---|
1O KGs PACKAGE | 3-4 WEEKS |
20 KGs PACKAGE | 8-9 WEEKS |
IDEAL WEIGHT PACKAGE | 14-16 WEEKS |
AVERAGE WEIGHT LOSS |
---|
Through our programs we have an average weight loss of 3—5 KGs/week and 10—15 KGs/ month. |
ACHIEVEMENTS |
---|
We have a total of 30,000 customers from 7 different countries and 3ó different nationalities achieved 3ó3,000 KGs of lat loss during 3 years. |
Dubai, Silicon Oasis Building A1 +9B2781979791
Jordon, Ammon,
Abdullah Ghosheh, 4ó. 101
+97145490330
Also Aviable in
Blood Test | Before | After | Normal Range |
---|---|---|---|
Cholesterol | 199 mg/dL | 14ó mg/dL | *200 mg/dL |
Triglycerides | 157 mg/dL | 130 mg/dL | <150 mg/dL |
LDL Cholesterol | J37 mg/dL | 92 mg/dL | <100 mg/dL |
HOMA2 - IR | 2.3 | 0.5 | < 1.8 |
g-GT serum | 36 U/L | 23 U/L | 29 U/L |
Talal was experiencing increasing weight, leading to concerns about his long-termhealth; his visceral fat levels were elevated, putting him at risk for metabolic issues, including insulin resistance.
Talal’s weight loss resulted in a significant improvement in visceral fat levels, which is a major risk factor for metabolic complications such as type 2 diabetes. Consequently, there was a marked enhancement in insulin sensitivity, leading to improved pancreatic function. Additionally, liver function showed improvement, thereby reducing the likelihood of non—alcoholic fatty liver disease (NAFLD). Periodic laboratory tests indicated a decrease in low density lipoprotein (LDL) levels, which contributes to better cardiovascular health.
Weight Loss Summary: Lost 13 kg (10 kg of body fat and 5 layers of visceral fat). The loss of visceral fat led to improved insulin sensitivity, reduced metabolic risk, and enhanced overall health, particularly regarding pancreatic and liver function. Improved cardiovascular markers indicate a healthier future for Talal.
Blood Test | Before | After | Normal Range |
---|---|---|---|
Cholesterol | 254 mg/dL | 224 mg/dL | <200 mg/dL |
LDL - Cholesterol | 160 mg/dL | 155 mg/dL | <100 mg/dL |
Triglycerides | 218 mg/dL | 107 mg/dL | <150 mg/dL |
HbA1C | 7.0 % | 5,2 % | 4.8-5.7% |
Fasting Blod Sugar | 129 mg/dL | 93 mg/dL | 70-P9 mg/dL |
Uric acid | 10.1 mg/dL | 7.7 mg/dL | 3.4-7.0 mg/dL |
Khalil had a significant weight issue, characterized by high visceral fat and, elevated fasting blood glucose levels. His cholesterol levels were also concerning, indicating a higher risk for cardiovascular disease.
The substantial weight loss, particularly in visceral fat, resulted in a significant improvement in insulin sensitivity, leading to a marked decrease in fasting blood glucose levels from 129 mg/dL to 93 mg/dL. Additionally, the HbAlc levels improved from 7 to 5.2 , indicating better long-term glycemic control. Laboratory results indicated a reduction in triglyceride levels from 218 mg/dL to 107 mg/dL, alongside a decrease in LDL levels, thereby reducing the risk of cardiovascular disease.
Furthermore, uric acid levels decreased from 10.1 mg/dL to 7.7 mg/dL, reflecting improved metabolic health and a reduced risk of gout.
Weight Loss Summary: Lost 4ó kg (34 kg of body fat and 8 layers of visceral fat). Khalil’s significant weight loss resulted in improved plycemic control and reduced cardiovascular risk factors, showcasing the medical benefits of effective weight management.
Blood Test | Before | After | Normal Range |
---|---|---|---|
Uric Acid | 8.0 mg/dL | 6.1 mg/dL | 3.4-7 mg/dL |
AST | 47 U/L | 20 U/L | Up to 40 U/L |
ALT | 32 U/L | 17 U/L | Up to 41 U/L |
Fasting Blood Sugar | 100 mg/dL | 88 mg/dL | 70-99 mg/dL |
HbA1c | 5.2% | 4.9% | <5.7% |
LDL Cholesterol | 123 mg/dL | 116 mg/dL | <100 mg/dL |
CPK | 238 U/L | 83 U/L | 20-200 U/L |
Husam had high levels of visceral fat, contributing to borderline fasting blood glucose levels and elevated uric acid levels, which increased his risk for gout. He also faced potential heart issues due to elevated cardiac enzymes.
The reduction in visceral fat contributed to significant improvements in fasting blood glucose levels, enhancing glycemic control, with levels decreasing from 100 mg/dL to 88 mg/dL. Laboratory analyses indicated a marked decrease in uric acid levels, dropping from 8 mg/dL to 6.1 mg/dL, thus reducing the risk of gout. Cardiac enzyme levels, specifically CPK, showed notable improvement, alongside enhanced liver enzyme levels. Total cholesterol levels also improved, with significant reductions in ALT and AST levels, indicating decreased liver fat and improved hepatic function.
Lost 14 kg (11 kg of body fat and 4 layers of visceral fat). The reduction in visceral fat led to improved glycemic control and lower uric acid levels, significantly decreasing the risk of gout and other metabolic issues, showcasing the health benefits of the diet.
Blood Test | Before | After | Normal Range |
---|---|---|---|
Fasting blood sugar | 102 mg/dL | 92 mg/dL | 70-99 mg/dL |
Uric acid | 6.4 mg/dL | 5.3 mg/dL | 2.4-5.7 mg/dL |
Triglycerides | 194 mg/dL | 103 mg/dL | <150 mg/dL |
Cholesterol | 169 mg/dL | 137 mg/dL | <200 mg/dL |
Insulin resistance | 1.08 | 0.38 | Up to 1.8 |
Silvia was dealing with excess body fat, particularly visceral fat, which negatively impacted her insulin response and overall metabolic health. Her fasting blood glucose levels were above normal, indicating potential prediabetes.
The considerable loss of fat, particularly visceral fat, contributed to enhanced insulin responsiveness, as evidenced by a decrease in fasting blood glucose levels from 102 mg/dL to 92 mg/dL.
Analyses revealed a substantial reduction in uric acid levels from 6.4 mg/dL to 5.3 mg/dL, along with improvements in cholesterol and triglyceride levels. Triglycerides decreased from 194 mg/dL to 103 mg/dL.
Weight Loss Summary: Silvia lost 18 kg (16 kg of fat and 4 layers of visceral fat). The considerable fat loss resulted in enhanced insulin sensitivity and reduced cholesterol levels, demonstrating significant health improvements and lowering the risk of metabolic complications.
Blood Test | Before | After | Normal Range |
---|---|---|---|
Total Cholesterol | 316 mg/dL | 187 mg/dL | <200 mg/dL |
LDL Cholesterol | 237.80 mg/dL | 119.80 mg/dL | <100 mg/dL |
Triglycerides | 151 mg/dL | 101 mg/dL | <150 mg/dL |
Uric acid | 11.3 mg/dL | 6.8 mg/dL | 2.4-6.1 mg/dL |
Abeer was struggling with high levels of visceral fat and had concerning lipid profiles, with elevated triglycerides and uric acid, increasing her risk for cardiovascular disease and gout.
The loss of visceral fat resulted in significant improvements in triglyceride levels, decreasing from 151 mg/dL to 101 mg/dL, and low-density lipoprotein (LDL) cholesterol, contributing to enhanced cardiovascular health.
Additionally, uric acid levels showed a notable decrease from 11.3 mg/dL to 6.8 mg/dL, reducing the risk of gout.
Weight Loss Summary: Lost 18 kg (14.3 kg of fat and 4 layers of visceral fat).
Abeer experienced marked improvements in triglyceride and uric acid levels, reflecting better cardiovascular health and a decreased risk of gout, reinforcing the benefits of her dietary changes.
Blood Test | Before | After | Normal Range |
---|---|---|---|
Cholesterol | 254 mg/dL | 224 mg/dL | <200 mg/dL |
LDL - Cholesterol | 160 mg/dL | 155 mg/dL | <100 mg/dL |
Triglycerides | 218 mg/dL | 107 mg/dL | <150 mg/dL |
HbA1C | 7.0 % | 5,2 % | 4.8-5.7% |
Fasting Blod Sugar | 129 mg/dL | 93 mg/dL | 70-P9 mg/dL |
Uric acid | 10,1 mg/dL | 7,7 mg/dL | 3.4-SO mg/dL |
Raed’s weight was impacting his insulin sensitivity, with high fasting blood glucose levels and elevated triglycerides. His health risks were compounded by high uric acid levels.
The loss of weight and visceral fat resulted in improved insulin sensitivity, reflected by a reduction in fasting blood glucose levels from 168 mg/dL to 90 mg/dL.
Tests indicated improvement in triglyceride levels, which dropped from 276 mg/dL to 91 mg/dL, along with a significant reduction in uric acid levels from 7.5 mg/dL to 7.3 mg/dL, thereby decreasing the risk of gout.
Liver enzymes, particularly ALT and AST, improved, indicating better overall liver function.
Weight Loss Summary: Lost 22 kg (13 kg of fat and 8.5 layers of visceral fat).
Raed’s substantial weight loss enhanced insulin sensitivity and overall metabolic health, significantly lowering his risk of diabetes and improving liver function.
Blood Test | Before | After | Normal Range |
---|---|---|---|
Cholesterol | 254 mg/dL | 224 mg/dL | <200 mg/dL |
LDL - Cholesterol | 160 mg/dL | 155 mg/dL | <100 mg/dL |
Triglycerides | 218 mg/dL | 107 mg/dL | <150 mg/dL |
HbA1C | 7.0 % | 5,2 % | 4.8-5.7% |
Fasting Blod Sugar | 129 mg/dL | 93 mg/dL | 70-P9 mg/dL |
Uric acid | 10,1 mg/dL | 7,7 mg/dL | 3.4-SO mg/dL |
Emad faced significant health risks due to his weight, including elevated blood glucose and triglyceride levels, as well as high uric acid, making him susceptible to developing type 2 diabetes and cardiovascular disease.
The significant weight loss resulted in a major improvement in glycemic control, with tests showing a decrease in HbA1c levels from %6.1 to %5.6, thereby reducing the risk of developing type 2 diabetes. Triglyceride and cholesterol levels also improved markedly, with triglycerides dropping from 310 mg/dL to 180 mg/dL. Insulin resistance improved significantly, and uric acid levels decreased from 7.7 mg/dL to 5.7 mg/dL, reducing the risk of gout.
Weight Loss Summary: Lost 40 kg (32 kg of fat). Emad’s dramatic weight loss resulted in improved glycemic control and reduced cardiovascular risks, highlighting the profound medical benefits associated with significant weight loss.
Blood Test | Before | After | Normal Range |
---|---|---|---|
Cholesterol | 254 mg/dL | 224 mg/dL | <200 mg/dL |
LDL - Cholesterol | 160 mg/dL | 155 mg/dL | <100 mg/dL |
Triglycerides | 218 mg/dL | 107 mg/dL | <150 mg/dL |
HbA1C | 7.0 % | 5,2 % | 4.8-5.7% |
Fasting Blod Sugar | 129 mg/dL | 93 mg/dL | 70-P9 mg/dL |
Uric acid | 10,1 mg/dL | 7,7 mg/dL | 3.4-SO mg/dL |
Noura had high visceral fat levels, leading to insulin resistance and elevated fasting blood glucose levels. Her lipid profile indicated risks for cardiovascular issues.
The loss of visceral fat contributed to an improved insulin response, with tests showing a decrease in insulin resistance levels from 6.9 to 2.3. Improvements in triglyceride and total cholesterol levels were noted, with triglycerides declining from 159 mg/dL to 113 mg/dL. Fasting blood glucose levels also showed improvement, decreasing from 115 mg/dL to 105 mg/dL.
Weight Loss Summary: Lost 7.5 kg (4.5 kg of fat and 2.5 layers of visceral fat). Noura’s weight loss improved her insulin response and reduced triglyceride levels, enhancing her overall health profile and underscoring the effectiveness of her dietary regimen.